Skip to main content
. 2022 Mar 3;6(5):1490–1498. doi: 10.1182/bloodadvances.2021005357

Figure 3.

Figure 3.

PFS in those finishing study therapy. PFS starts at the end of therapy and compares those that were treated with IBR (red) to those that were not (blue).